Relevant bibliographies by topics / Heart failure with reduced ejection fraction

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Heart failure with reduced ejection fraction'

Author: Grafiati
Published: 4 June 2021
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Heart failure with reduced ejection fraction.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Heart failure with reduced ejection fraction"

1

Shah, Dr Reena, Dr Sunita J. Solanki, Dr Prakash patel, and Dr Neeraj Singh Dr.Neeraj Singh. "Study of Incidence of Heart Failure with Reduced Ejection Fraction and Heart Failure with Normal Ejection Fraction." International Journal of Scientific Research 2, no. 10 (June 1, 2012): 1–2. http://dx.doi.org/10.15373/22778179/oct2013/104.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gottlieb, Sheldon H. "Heart Failure With Reduced Ejection Fraction." Journal of the American College of Cardiology 78, no. 20 (November 2021): 2013–16. http://dx.doi.org/10.1016/j.jacc.2021.09.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Murphy, Sean P., Nasrien E. Ibrahim, and James L. Januzzi. "Heart Failure With Reduced Ejection Fraction." JAMA 324, no. 5 (August 4, 2020): 488. http://dx.doi.org/10.1001/jama.2020.10262.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Steahr, Gregg, Linda Kelly, Meredith Moore, and Brenda Hott. "Heart Failure Preserved Ejection Fraction Patients Benefit From Heart Failure Reduced Ejection Fraction Guidelines." Journal of Cardiac Failure 21, no. 8 (August 2015): S73—S74. http://dx.doi.org/10.1016/j.cardfail.2015.06.232.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Butler, Javed, Milton Packer, Gerasimos Filippatos, Joao Pedro Ferreira, Cordula Zeller, Janet Schnee, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, and Stefan D. Anker. "Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction." European Heart Journal 43, no. 5 (December 8, 2021): 416–26. http://dx.doi.org/10.1093/eurheartj/ehab798.

Full text
Abstract:
Abstract Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the entire range of ejection fractions seen in clinical practice. We assessed the influence of ejection fraction on the effect of the sodium–glucose cotransporter 2 inhibitor empagliflozin on heart failure outcomes. Methods and results A pooled analysis was performed on both the EMPEROR-Reduced and EMPEROR-Preserved trials (9718 patients; 4860 empagliflozin and 4858 placebo), and patients were grouped based on ejection fraction: <25% (n = 999), 25–34% (n = 2230), 35–44% (n = 1272), 45–54% (n = 2260), 55–64% (n = 2092), and ≥65% (n = 865). Outcomes assessed included (i) time to first hospitalization for heart failure or cardiovascular mortality, (ii) time to first heart failure hospitalization, (iii) total (first and recurrent) hospitalizations for heart failure, and (iv) health status assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ). The risk of cardiovascular death and hospitalization for heart failure declined progressively as ejection fraction increased from <25% to ≥65%. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization, mainly by reducing heart failure hospitalizations. Empagliflozin reduced the risk of heart failure hospitalization by ≈30% in all ejection fraction subgroups, with an attenuated effect in patients with an ejection fraction ≥65%. Hazard ratios and 95% confidence intervals were: ejection fraction <25%: 0.73 (0.55–0.96); ejection fraction 25–34%: 0.63 (0.50–0.78); ejection fraction 35–44%: 0.72 (0.52–0.98); ejection fraction 45–54%: 0.66 (0.50–0.86); ejection fraction 55–64%: 0.70 (0.53–0.92); and ejection fraction ≥65%: 1.05 (0.70–1.58). Other heart failure outcomes and measures, including KCCQ, showed a similar response pattern. Sex did not influence the responses to empagliflozin. Conclusion The magnitude of the effect of empagliflozin on heart failure outcomes was clinically meaningful and similar in patients with ejection fractions <25% to <65%, but was attenuated in patients with an ejection fraction ≥65%. Key Question How does ejection fraction influence the effects of empagliflozin in patients with heart failure and either a reduced or a preserved ejection fraction? Key Finding The magnitude of the effect of empagliflozin on heart failure outcomes and health status was similar in patients with ejection fractions <25% to <65%, but it was attenuated in patients with an ejection fraction ≥65%. Take Home Message The consistency of the response in patients with ejection fractions of <25% to <65% distinguishes the effects of empagliflozin from other drugs that have been evaluated across the full spectrum of ejection fractions in patients with heart failure.
APA, Harvard, Vancouver, ISO, and other styles
6

Johansson, Isabelle, Ulf Dahlström, Magnus Edner, Per Näsman, Lars Rydén, and Anna Norhammar. "Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function." Diabetes and Vascular Disease Research 15, no. 6 (September 3, 2018): 494–503. http://dx.doi.org/10.1177/1479164118794619.

Full text
Abstract:
Objective: To study the characteristics and prognostic implications of type 2 diabetes in different heart failure entities from a nationwide perspective. Methods: This observational study comprised 30,696 heart failure patients prospectively included in the Swedish Heart Failure Registry (SwedeHF) 2003–2011 from specialist care, with mortality information available until December 2014. Patients were categorized into three heart failure entities by their left ventricular ejection fraction (heart failure with preserved ejection fraction: ⩾50%, heart failure with mid-range ejection fraction: 40%–49% and heart failure with reduced ejection fraction: <40%). All-cause mortality stratified by type 2 diabetes and heart failure entity was studied by Cox regression. Results: Among the patients, 22% had heart failure with preserved ejection fraction, 21% had heart failure with mid-range ejection fraction and 57% had heart failure with reduced ejection fraction. The proportion of type 2 diabetes was similar, ≈25% in each heart failure entity. Patients with type 2 diabetes and heart failure with preserved ejection fraction were older, more often female and burdened with hypertension and renal impairment compared with heart failure with mid-range ejection fraction and heart failure with reduced ejection fraction patients among whom ischaemic heart disease was more common. Type 2 diabetes remained an independent mortality predictor across all heart failure entities after multivariable adjustment, somewhat stronger in heart failure with left ventricular ejection fraction below 50% (hazard ratio, 95% confidence interval; heart failure with preserved ejection fraction: 1.32 [1.22–1.43], heart failure with mid-range ejection fraction: 1.51 [1.39–1.65], heart failure with reduced ejection fraction: 1.46 [1.39–1.54]; p-value for interaction, p = 0.0049). Conclusion: Type 2 diabetes is an independent mortality predictor across all heart failure entities increasing mortality risk by 30%–50%. In type 2 diabetes, the heart failure with mid-range ejection fraction entity resembles heart failure with reduced ejection fraction in clinical characteristics, risk factor pattern and prognosis.
APA, Harvard, Vancouver, ISO, and other styles
7

Hicks, Albert, Jorge F. Velazco, Salman Gohar, Ahmed Seliem, Shelley A. Hall, and Jeffrey B. Michel. "Advanced heart failure with reduced ejection fraction." Baylor University Medical Center Proceedings 33, no. 3 (June 2, 2020): 350–56. http://dx.doi.org/10.1080/08998280.2020.1765663.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Moayedi, Yasbanoo, and Jeremy Kobulnik. "Chronic heart failure with reduced ejection fraction." Canadian Medical Association Journal 187, no. 7 (September 22, 2014): 518. http://dx.doi.org/10.1503/cmaj.140430.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Shaha, Kunal Bikram, Rikesh Tamrakar, Man Bahadur KC, Deewakar Sharma, Yadav Deo Bhatt, Sujeeb Rajbhandari, Rajit Sharma, and Rabindra Simkhada. "Heart failure with preserved ejection fraction; the other half of the heart failure, how it stands in 2013." Nepalese Heart Journal 10, no. 1 (February 1, 2014): 46–56. http://dx.doi.org/10.3126/njh.v10i1.9747.

Full text
Abstract:
Last two decade, heart failure with preserved ejection fraction was deprived from being considered as a part of spectrum of heart failure. May be heart failure with preserved ejection fraction was common but not recognized by cardiology fraternity. Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction each make up about half of the overall heart failure burden. But the paradox is: morbidity and mortality in heart failure with preserved ejection fraction despite being similar to patients with heart failure with reduced ejection fraction, today’s cardiology community has not much to offer in terms of mortality reducing treatment. The term diastolic heart failure has been well replaced by heart failure with preserved ejection fraction because multiple non-diastolic abnormalities in cardiovascular function also contribute to heart failure with preserved ejection fraction and diastolic dysfunction always accompanied heart failure with reduced ejection fraction. Diagnosis of heart failure with preserved ejection fraction is an uphill task since it relies upon careful clinical evaluation, doppler (pulse wave and tissue) echocardiography, and invasive hemodynamic assessment after exclusion of potential noncardiac causes of symptoms suggestive of heart failure. Patients with heart failure with preserved ejection fraction are usually older women with a history of hypertension. Obesity, coronary artery disease, diabetes mellitus, and atrial fibrillation are also highly prevalent in heart failure with preserved ejection fraction. Cornerstone of treatment of this entity revolves around treatment of underlying cause and symptom guided therapy. Nepalese Heart Journal | Volume 10 | No.1 | November 2013| Pages 46-56 DOI: http://dx.doi.org/10.3126/njh.v10i1.9747
APA, Harvard, Vancouver, ISO, and other styles
10

Habib, Mohammed. "Cost-Effectiveness Analysis of Dapagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction." Clinical Cardiology and Cardiovascular Interventions 3, no. 1 (January 3, 2020): 01–03. http://dx.doi.org/10.31579/2641-0419/030.

Full text
Abstract:
Bakground: The Dapagliflozin was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril. Objective: To estimate the cost-effectiveness of Dapagliflozin in Gaza Design, Setting, and Participants: Quality of life was based on trial EQ-5D scores. Hospital costs combined Medicare and private insurance reimbursement rates; medication costs included the wholesale acquisition cost for sacubitril/valsartan and Dapagliflozin. were performed on key inputs including: hospital costs, mortality benefit, hazard ratio for hospitalization reduction, drug costs, and quality-of-life estimates. Main Outcomes and Measures: Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremental costs per QALY gained. Results: In DAPA HF trial: in patient with DM, the strategy of using dapagliflozin has an of $ 17287 per QALY gained and in patient without DM, the strategy of using dapagliflozin has an of $ 45192 per QALY gained. Indirect comparison between patients with dapagliflozin but without DM the strategy of using sacubitril/ valsartan has an ICER of $ 66000 per QALY gained and in patient with DM, ICER of 94 000 $ per QALY gained. Conclusions: For eligible patients with HF and reduced ejection fraction, Dapagliflozin was cost effective than the sacubitril/valsartan in Gaza.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Heart failure with reduced ejection fraction"

1

Mbasu, Richard Juma. "Distinguishing heart failure with preserved ejection fraction from heart failure with reduced ejection fraction using proteomics techniques." Thesis, University of Leicester, 2016. http://hdl.handle.net/2381/39013.

Full text
Abstract:
Heart failure is the second leading cause of morbidity and mortality in the world after cancer. In the UK, over 500,000 people are living with heart failure of which 30-40% die within 1 year of diagnosis. Some biomarkers for diagnosis and prognosis of heart failure have been established. However, they suffer from poor levels of accuracy and efficacy and their roles in clinical use is poorly understood. Thus, new biomarkers are needed. In this research, mass spectrometry based proteomics was used to profile patients plasma for clinical biomarker discovery due to its ability to perform both quantitative and qualitative protein profiling on clinical samples. Ninety samples from control, heart failure with preserved ejection fraction and heart failure with reduced ejection fraction subjects were used. Plasma protein profiling was performed using an optimised UPLC-IMS-DIA-MSE label free quantitation method. Bioinformatics analysis was used to analyse the changes observed in the protein profiles to identify potential biomarkers of heart failure. A novel method, termed mixed mode matrix was used for pilot study prior to main study with lipid removal agent. Samples were analysed using Waters Synapt G2S HDMS QToF mass spectrometer in triplicate on positive mode electrospray ionisation. Statistical comparisons of protein profiles was carried out using Progenesis LC-MS prior to data mining using SPSS, RapidMiner and SIMCA 14 to identify potential biomarkers. Thirty proteins were identified as potential biomarkers and shown to be involved in various pathophysiological processes leading to heart failure. ASL which plays role in nitrogen oxide production in the epithelium was upregulated in heart failure cohort. Conversely, GPX3 which scavenges free radicals in blood preventing apoptosis and necrosis of cells was downregulated in heart failure cohort. These two proteins were proposed as potential biomarkers for heart failure with preserved ejection fraction. Future studies to validate these biomarkers with the developed targeted LC-MS based MRM assay is needed.
APA, Harvard, Vancouver, ISO, and other styles
2

Barrett-O'Keefe, Zachary. "Cardiovascular control during exercise and the role of the sympathetic nervous system in heart failure with reduced ejection fraction." Thesis, The University of Utah, 2016. http://pqdtopen.proquest.com/#viewpdf?dispub=10001028.

Full text
Abstract:

The objective of this dissertation was to systematically investigate the hemodynamic response to exercise in heart failure with reduced ejection fraction (HFrEF) and healthy individuals of a similar age, with an emphasis on how the sympathetic nervous system (SNS) may contribute to the dysregulation of the cardiovascular system in this cohort. The first study aimed to determine how varying levels of metaboreceptor activation alters the mean arterial pressure (MAP) response as well as the degree in which cardiac output (CO) and systemic vascular conductance (SVC) contribute to the metaboreflex-induced increase in MAP. We observed similar increases in MAP induced by metaboreceptor activation in both groups; however, this response was driven primarily by increases in CO in the control group and reductions in SVC in the HFrEF group. These data suggest a preserved role of the metaboreflex-induced increase in MAP in HFrEF, but suggest that this response is governed by the peripheral circulation in this cohort, a maladaptation that may exacerbate systolic dysfunction through an increase in afterload. The second study of this dissertation was focused on investigating the peripheral vasodilatory and hyperemic response to exercise in isolation of central hemodynamic limitations in both the upper and lower limbs. This study documented an impaired hyperemic response to both static-intermittent handgrip exercise as well as dynamic single-leg knee-extensor exercise in HFrEF patients - impairments primarily attributed to vasodilatory dysfunction, as the increase in MAP induced by these exercise modalities was preserved compared to healthy individuals. Together, these findings have identified a significant attenuation of the exercise-induced hyperemic response during both upper and lower limb exercise, implicating maladaptions in the peripheral hemodynamic response to exercise as a potential contributor limiting exercise capacity in this patient group. The third study sought to address the contribution of the alpha-adrenergic receptor pathway in the regulation of blood flow to exercising skeletal muscle in HFrEF patients. At rest, alpha-1-adrenergic receptor vasoconstriction induced by local intra-arterial infusion of phenylephrine (PE) was reduced in HFrEF compared to control subjects. During exercise, the vasoconstrictor responsiveness to PE was significantly attenuated in the control group and preserved in HFrEF patients compared to rest. Additionally, nonspecific alpha-adrenergic receptor antagonism induced by local intra-arterial infusion of phentolamine increased blood flow to a greater degree in HFrEF compared to the control subjects, both at rest and during exercise. Together, these findings demonstrate a marked contribution of alpha-adrenergic receptor restraint of leg blood flow in HFrEF patients during exercise. Collectively, these three studies have provided new insight into the role the SNS and peripheral hemodynamics play in the maladaptive cardiovascular response to exercise displayed in patients with HFrEF, further implicating the peripheral expression of SNS activity as a primary contributor to impaired exercise capacity in this patient group.

APA, Harvard, Vancouver, ISO, and other styles
3

Lanfermann, Simon Verfasser], and Tanja [Akademischer Betreuer] [Zeller. "Novel Biomarkers in Heart Failure with Reduced and Preserved Ejection Fraction in the General Population / Simon Lanfermann ; Betreuer: Tanja Zeller." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2020. http://nbn-resolving.de/urn:nbn:de:gbv:18-104233.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lanfermann, Simon [Verfasser], and Tanja [Akademischer Betreuer] Zeller. "Novel Biomarkers in Heart Failure with Reduced and Preserved Ejection Fraction in the General Population / Simon Lanfermann ; Betreuer: Tanja Zeller." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2020. http://d-nb.info/1212180941/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rariden, Brandi Scot. "Sedentary Time and the Cumulative Risk of Preserved and Reduced Ejection Fraction Heart Failure: from the Multi-Ethnic Study of Atherosclerosis." UNF Digital Commons, 2018. https://digitalcommons.unf.edu/etd/792.

Full text
Abstract:
ABSTRACT Purpose: The purpose of this study was to examine the relationship between self-reported sedentary time (ST) and the cumulative risk of preserved ejection fraction heart failure (HFpEF) and reduced ejection fraction heart failure (HFrEF) using a diverse cohort of U.S. adults 45-84 years of age. Methods: Using data from the Multi-Ethnic Study of Atherosclerosis (MESA), we identified 6,814 subjects (52.9% female). All were free of baseline cardiovascular disease. Cox regression was used to calculate the hazard ratios (HR) associated with baseline ST and risk of overall heart failure (HF), HFpEF, and HFrEF. Weekly self-reported ST was dichotomized based on the 75th percentile (1,890 min/wk). Results: During an average of 11.2 years of follow-up there were 178 first incident HF diagnoses; 74 HFpEF, 69 HFrEF and 35 with unknown EF. Baseline ST >1,890 min/wk was significantly associated with an increased risk of HFpEF (HR [95% CI]; 1.87 [1.13 – 3.09], p= 0.01), but not HFrEF (HR [95% CI]; 1.30 [0.78 – 2.15], p= 0.32). The relationship with HFpEF remained significant in separate fully adjusted models including either waist circumference (HR [95% CI]; 2.16 [1.23 – 3.78], p < 0.01) or body mass index (HR [95% CI]; 2.17 [1.24 – 3.80], p < 0.01). Additionally, every 60 minute increase in weekly ST was associated with a significant 3% increased risk of HFpEF (HR [95% CI]; 1.03 [1.01 – 1.05], p < 0.01). Conclusions: Sedentary time > 1,890 min/wk (~4.5 h/d) is a significant independent predictor of HFpEF, but not HFrEF.
APA, Harvard, Vancouver, ISO, and other styles
6

Jonsson, Åsa. "How to create and analyze a Heart Failure Registry with emphasis on Anemia and Quality of Life." Doctoral thesis, Linköpings universitet, Avdelningen för kardiovaskulär medicin, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-137351.

Full text
Abstract:
Background and aims Heart failure (HF) is a major cause of serious morbidity and death in the population and one of the leading medical causes of hospitalization among people older than 60 years. The aim of this thesis was to describe how to create and how to analyze a Heart Failure Registry with emphasis on Anemia and Quality of Life. (Paper I) We described the creation of the Swedish Heart Failure Registry (SwedeHF) as an instrument, which may help to optimize the handling of HF patients and show how the registry can be used to improve the management of patients with HF. (Paper II) In order to show how to analyze a HF registry we investigated the prevalence of anemia, its predictors, and its association with mortality and morbidity in a large cohort of unselected patients with HFrEF included in the SwedeHF, and to explore if there are subgroups of HF patients identifying high--‐risk patients in need of treatment. (Paper III) In order to show another way of analyzing a HF registry we assessed the prevalence of, associations with, and prognostic impact of anemia in patients with HFmrEF and HFpEF. (Paper IV) Finally we examined the usefulness of EQ--‐ 5D as a measure of patient--‐reported outcomes among HF patients using different analytical models and data from the SwedeHF, and comparing results about HRQoL for patients with HFpEF and HFrEF. Methods An observational study based on the SwedeHF database, consisting of about 70 variables, was undertaken to describe how a registry is created and can be used (Paper I). One comorbidity (anemia) was applied to different types of HF patients, HFrEF (EF <40%) (II) and HFmrEF (EF 40--‐49% ) or HFpEF (> 50%) (III) analyzing the data with different statistical methods. The usefulness of EQ--‐5D as measure of patient--‐ reported outcomes was studied and the results about HRQoL were compared for patients with HFpEF and HFrEF (IV). Results In the first paper (Paper I) we showed how to create a HF registry and presented some characteristics of the patients included, however not adjusted since this was not the purpose of the study. In the second paper (Paper II) we studied anemia in patients with HFrEF and found that the prevalence of anemia in HFrEF were 34 % and the most important independent predictors were higher age, male gender and renal dysfunction. One--‐year survival was 75 % with anemia vs. 81 % without (p<0,001). In the matched cohort after propensity score the hazard ratio associated with anemia was for all--‐cause death 1.34. Anemia was associated with greater risk with lower age, male gender, EF 30--‐39%, and NYHA--‐class I--‐II. In the third paper (Paper III) we studied anemia in other types of HF patients and found that the prevalence in the overall cohort in patients with EF > 40% was 42 %, in HFmrEF 38 % and in HFpEF (45%). Independent associations with anemia were HFpEF, male sex, higher age, worse New York Heart Association class and renal function, systolic blood pressure <100 mmHg, heart rate ≥70 bpm, diabetes, and absence of atrial fibrillation. One--‐year survival with vs. without anemia was 74% vs. 89% in HFmrEF and 71% vs. 84% in HFpEF (p<0.001 for all). Thus very similar results in paper II and III but in different types of HF patients. In the fourth paper (Paper IV) we studied the usefulness of EQ--‐5D in two groups of patients with HF (HFpEF and HFrEF)) and found that the mean EQ--‐5D index showed small reductions in both groups at follow--‐up. The patients in the HFpEF group reported worsening in all five dimensions, while those in the HFrEF group reported worsening in only three. The Paretian classification showed that 24% of the patients in the HFpEF group and 34% of those in the HFrEF group reported overall improvement while 43% and 39% reported overall worsening. Multiple logistic regressions showed that treatment in a cardiology clinic affected outcome in the HFrEF group but not in the HFpEF group (Paper IV). Conclusions The SwedeHF is a valuable tool for improving the management of patients with HF, since it enables participating centers to focus on their own potential for improving diagnoses and medical treatment, through the online reports (Paper I). Anemia is associated with higher age, male gender and renal dysfunction and increased risk of mortality and morbidity (II, III). The influence of anemia on mortality was significantly greater in younger patients in men and in those with more stable HF (Paper II, III). The usefulness of EQ--‐5D is dependent on the analytical method used. While the index showed minor differences between groups, analyses of specific dimensions showed different patterns of change in the two groups of patients (HFpEF and HFrEF). The Paretian classification identified subgroups that improved or worsened, and can therefore help to identify needs for improvement in health services (Paper IV).
APA, Harvard, Vancouver, ISO, and other styles
7

Sharp, III Thomas E. "DRUG AND CELL–BASED THERAPIES TO REDUCE PATHOLOGICAL REMODELING AND CARDIAC DYSFUNCTION AFTER ACUTE MYOCARDIAL INFARCTION." Diss., Temple University Libraries, 2017. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/445275.

Full text
Abstract:
Physiology
Ph.D.
Remarkable advances have been made in the treatment of cardiovascular diseases (CVD), however, CVD still accounts for the most deaths in industrialized nations. Ischemic heart disease (IHD) can lead to acute coronary syndrome (ACS) (myocardial infarction [MI]). The standard of care is reperfusion therapy followed by pharmacological intervention to attenuate clinical symptoms related to the MI. While survival from MI has dramatically increased with the implementation of reperfusion therapy, these individuals will inevitably suffer progressive pathological remodeling leaving them predispose to develop heart failure (HF). HF is a clinical syndrome defined as the impairment of the heart to maintain organ perfusion at rest and/or during times of exertion (i.e. exercise intolerance). Clinically, this is accompanied by dyspnea, pulmonary or splanchnic congestion and peripheral edema. Physiologically, there is neurohormal activation through the classical β–adrenergic and PKA–dependent signalin
Temple University--Theses
APA, Harvard, Vancouver, ISO, and other styles
8

Phan, Thanh Trung. "The pathophysiology of heart failure with preserved ejection fraction." Thesis, University of Birmingham, 2010. http://etheses.bham.ac.uk//id/eprint/828/.

Full text
Abstract:
Our studies demonstrate that patients with HfpEF have impaired myocardial energetics as indicated by the diminished in vivo myocardial PCr/ATP ratio. Data acquired during semi-supine cycling exercise indicates that patients with HfpEF had a dynamic impairment of LV active relaxation. In addition, ventricular-vascular coupling ratio was unchanged during exercise in HfpEF patients in contrast to healthy controls where the ratio fell substantially during exercise. In addition, we found patients with HfpEF with normal LA dimensions had increased LA contribution during exercise as compared to controls. Furthermore, we showed patients with HfpEF exhibited contractile inefficiency as well as systolic and diastolic dyssynchrony as measured by speckle tracking imaging (STI). And that the LV anterior wall appears to be the most delayed segment. We also demonstrated that HfpEF patients exhibited chronotropic incompetence during peak exercise testing and abnormal HR recovery following exercise compared to age-gender-matched healthy controls and hypertensive patients. In a separate study, we showed that changes in LV torsion, untwist and LV strain and strain rate in patients with HfpEF at rest were similar to changes found in normal aging.
APA, Harvard, Vancouver, ISO, and other styles
9

Patel, Hitesh Chandrakant. "Renal denervation in heart failure with preserved ejection fraction." Thesis, Imperial College London, 2016. http://hdl.handle.net/10044/1/42993.

Full text
Abstract:
There are no treatments proven to significantly reduce heart failure hospitalisations or mortality in patients with heart failure with preserved ejection fraction (HFpEF). Activity of the sympathetic nervous system (SNS) is elevated in heart failure regardless of ejection fraction and may be an important target in HFpEF. Renal denervation (RDT) is a percutaneous technique that seeks to attenuate SNS activity. The aim of this thesis was to investigate the role of RDT in patients with HFpEF. A randomised (2:1) open-controlled trial with blinded endpoint analysis was planned. 10 228 patients were screened for the Renal DenervaTion in heart failure with Preserved Ejection Fraction trial (RDT-PEF), and ultimately 25 were randomised (17 received RDT and 8 were allocated to the open control arm). The primary endpoint was an improvement in a minimum of three out of the following six surrogate endpoints: Minnesota Living with Heart Failure questionnaire score, peak oxygen uptake on exercise, B-type natriuretic peptide, E/e' from echocardiography, left atrial volume from cardiac magnetic resonance imaging (CMR) and left ventricular mass from (CMR). The primary endpoint was not met but the study was underpowered. On post-hoc analysis there was an improvement in a composite score of all six endpoint in the RDT arm compared to the control arm at three months but this did not persist to 12 months. The study satisfied its safety endpoints. However, two patients required balloon angioplasty during the RDT procedure for significant renal artery spasm/oedema. RDT had no effect on blood pressure, renal function, vascular function, renin-angiotensin system or SNS activity. In summary, this thesis has shown that HFpEF is not as prevalent as reported. RDT did not improve quality of life, exercise function, biomarkers and left heart remodelling in HFpEF. The procedure was safe though not without complications in patients with HFpEF.
APA, Harvard, Vancouver, ISO, and other styles
10

Ma, Chao [Verfasser]. "Evaluation of mouse models of heart failure with preserved ejection fraction / Chao Ma." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2021. http://d-nb.info/123498489X/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Heart failure with reduced ejection fraction"

1

De Sutter, Johan, Piotr Lipiec, and Christine Henri. Heart failure: preserved left ventricular ejection fraction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0028.

Full text
Abstract:
Nearly half of all patients with heart failure present with a preserved left ventricular ejection fraction (HFPEF). HFPEF is a pathophysiologically and clinically heterogeneous disease with an overall similar outcome to heart failure patients with a reduced ejection fraction. It is predominantly seen in elderly patients and comorbidities such as obesity, diabetes, hypertension, a sedentary lifestyle, and myocardial ischaemia play important roles in its development. In this chapter the conventional echocardiographic hallmarks of HFPEF including a preserved ejection fraction, left ventricular hypertrophy, left atrial dilatation, diastolic dysfunction, and pulmonary hypertension are presented. For the evaluation of left ventricular diastolic dysfunction, it is important to keep in mind that no single echocardiographic parameter is sufficiently accurate and reproducible to be used in isolation to make a diagnosis of diastolic dysfunction. The value of newer techniques including three-dimensional echocardiography and longitudinal strain assessment for the diagnosis and follow-up of HFPEF patients are promising but require further evaluation. As exercise-induced dyspnoea may be the first manifestation of HFPEF, the role of exercise echo (or diastolic stress testing) with evaluation of exercise-induced changes in left ventricular filling pressure and pulmonary artery systolic pressure is also presented. This chapter ends with a discussion on the echocardiographic parameters that can be used for risk stratification and follow-up of HFPEF patients.
APA, Harvard, Vancouver, ISO, and other styles
2

Randerath, Winfried J., and Shahrokh Javaheri. Sleep and the heart. Edited by Sudhansu Chokroverty, Luigi Ferini-Strambi, and Christopher Kennard. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199682003.003.0040.

Full text
Abstract:
Heart function and sleep are closely associated. While NREM sleep reduces cardiac workload, phasic REM sleep increases sympathetic activity and cardiac vulnerability. Heart failure (HF) patients suffer from disturbed sleep due to frequent awakenings, periodic limb movements, sleep apnea, and depression. Insomnia seems to be associated with incident HF, and, when comorbid, results in a vicious circle. There is much evidence of a relationship between breathing disturbances during sleep and heart diseases. At least 50% of HF patients suffer from obstructive (OSA) or central (CSA) sleep apnea, both associated with impaired prognosis. OSA is a risk factor for arterial hypertension, atrial fibrillation, and HF. Continuous positive airway pressure devices reduce adverse cardiac events and improve outcome in severe OSA in compliant subjects. Adaptive servoventilation (ASV) is superior to other therapeutic options for CSA. However, the use of ASV is contraindicated in severe HF with reduced, but not preserved, ejection fraction.
APA, Harvard, Vancouver, ISO, and other styles
3

Smiseth, Otto A., Maurizio Galderisi, and Jae K. Oh. Left ventricle: diastolic function. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198726012.003.0021.

Full text
Abstract:
Evaluation of diastolic function by echocardiography is useful to diagnose heart failure with preserved ejection fraction by showing signs of diastolic dysfunction, and regardless of ejection fraction, echocardiography can be used to estimate left ventricular (LV) filling pressure. Diastolic dysfunction occurs in a number of cardiac diseases other than heart failure and mild diastolic dysfunction is part of the normal ageing process. The fundamental disturbances in diastolic dysfunction are slowing of myocardial relaxation, loss of restoring forces, and reduced LV chamber compliance. As a compensatory response there is elevated LV filling pressure. Slowing of relaxation and loss of restoring forces are reflected in reduction in LV early diastolic lengthening velocity (e?) by tissue Doppler. The reduced diastolic compliance is reflected in faster deceleration of early diastolic transmitral velocity by pulsed wave Doppler. Elevated LV filling pressure is reflected in a number of Doppler indices and in enlarged left atrium. This chapter reviews the physiology of diastolic function, the clinical methods and indices which are available, and how these should be applied.
APA, Harvard, Vancouver, ISO, and other styles
4

Paneni, Francesco, and Massimo Volpe. Co-morbidity (HFrEF and HFpEF): hypertension. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198784906.003.0415_update_001.

Full text
Abstract:
Hypertensive heart disease is a major cause of heart failure (HF) and mortality. Hypertension precedes HF occurrence in 75% of cases, and carries a sixfold increase in HF risk as compared to non-hypertensive individuals. Most importantly, a minority of patients survive 5 years after the onset of hypertensive HF. In hypertensive patients, the heart may present different patterns of adaptive remodelling: concentric remodelling, concentric hypertrophy, and eccentric hypertrophy. Although most hypertensive patients are at high risk of developing concentric hypertrophy, a growing proportion of subjects display a concentric-to-eccentric progression eventually leading to left ventricular dilation and systolic dysfunction. Several factors including myocardial ischaemia, ethnicity, genetic background, history of diabetes, and blood pressure pattern may significantly influence the pathway from hypertension to left ventricular dilation. Patients with a concentric hypertrophy usually develop HF with preserved ejection fraction (HFpEF), whereas those with an eccentric (dilated) phenotype develop HF with reduced ejection fraction (HFrEF). Lowering blood pressure has a striking effect in reducing the risk of HF. Although available antihypertensive drugs are all successful in lowering blood pressure, angiotensin-converting enzyme inhibitors, angiotensin receptor blocker (ARBs), and diuretics are more effective than other drug classes in preventing HF. The combination of the neprilysin inhibitor sacubitril with the ARB valsartan (LCZ696) has recently been shown to be highly effective in reducing HF-related outcomes in hypertensive subjects. An individualized treatment scheme taking into account blood pressure levels, type of HF (HFpEF or HFrEF), and relevant co-morbidities (i.e. renal disease, diabetes) is currently the best approach to improve morbidity and mortality in hypertensive patients with HF.
APA, Harvard, Vancouver, ISO, and other styles
5

Katritsis, Demosthenes G., Bernard J. Gersh, and A. John Camm. Heart failure with preserved left ventricular ejection fraction. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199685288.003.0805_update_003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lam, Carolyn S. P. Heart Failure with Preserved Ejection Fraction, an Issue of Heart Failure Clinics. Elsevier - Health Sciences Division, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Heart Failure with Preserved Ejection Fraction, An Issue of Heart Failure Clinics. Elsevier, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Garcia, Mario J., and Allan L. Klein. Diastology: Clinical Approach to Heart Failure with Preserved Ejection Fraction. Elsevier, 2021.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reffelmann, Thorsten, and Robert Kloner. Adjunctive Reperfusion Therapy Post-AMI. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199544769.003.0009.

Full text
Abstract:
• Reperfusion of the occluded coronary artery in an ST-segment-elevation myocardial infarction is the most effective approach for reducing infarct size, preserving left ventricular ejection fraction, lowering the incidence and severity of congestive heart failure and improving prognosis• Hence, several pharmacologic agents intended to improve target vessel patency as an adjunct to thrombolysis or primary percutaneous coronary intervention have been shown to be beneficial in patients with reperfusion therapy for acute myocardial infarction, namely antiplatelet and anticoagulation agents• Animal investigations have suggested that coronary reperfusion may also result in undesirable cardiac alterations, termed ‘reperfusion injury’, such as reversible contractile dysfunction (‘stunning’), microvascular obstruction (‘no-reflow’), and in several studies the progression of myocardial necrosis (‘lethal reperfusion injury’)• Clinical investigations of various pharmacologic interventions as an adjunctive therapy to reperfusion to reduce final infarct size, the amount of contractile dysfunction and to improve prognosis have been mostly inconsistent; only a few interventions, e.g. adenosine and atrial natriuretic peptide seem to show promise at least in certain subgroups.
APA, Harvard, Vancouver, ISO, and other styles
10

Hummel, Scott L., and Matthew C. Konerman. Heart Failure with Preserved Ejection Fraction, an Issue of Cardiology Clinics. Elsevier - Health Sciences Division, 2022.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Heart failure with reduced ejection fraction"

1

Cao, Jacob, John O'Sullivan, and Sean Lal. "Pathophysiology of Heart Failure with Reduced Ejection Fraction." In Heart Failure, 22–31. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9780429244544-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Jackson, Alice M., and Pardeep S. Jhund. "Heart Failure with Reduced Ejection Fraction." In Textbook of Vascular Medicine, 383–95. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16481-2_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rao, Prashant, and Marwa A. Sabe. "Heart Failure with Reduced Ejection Fraction." In Handbook of Outpatient Cardiology, 251–66. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-88953-1_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Senni, Michele, Emilia D’Elia, Michele Emdin, and Giuseppe Vergaro. "Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction." In Heart Failure, 79–108. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/164_2016_86.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Reid, Leah, Jonathan Murrow, Kent Nilsson, and Catherine Marti. "Outpatient Management of Stable Heart Failure with Reduced Ejection Fraction." In Heart Failure, 99–107. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9780429244544-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Psotka, Mitchell A., and John R. Teerlink. "Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction." In Heart Failure, 465–90. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/164_2017_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Rohani, Atooshe. "Doxorubicin Induced Heart Failure with Reduced Ejection Fraction." In Clinical Cases in Cardiology, 21–27. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71155-9_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ahmed, Ali, and Jerome L. Fleg. "Heart failure with reduced ejection fraction in older adults." In Tresch and Aronow’s Cardiovascular Disease in the Elderly, 406–21. Sixth edition. | Boca Raton, FL : CRC Press/Taylor & Francis Group, [2019]: CRC Press, 2019. http://dx.doi.org/10.1201/9781315151311-21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Rohani, Atooshe. "Carfilzomib (CFZ) Induced Heart Failure with Reduced Ejection Fraction." In Clinical Cases in Cardiology, 37–39. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71155-9_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Teichman, Sam L., Kassandra S. Thomson, and Michael Regnier. "Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction." In Heart Failure, 447–64. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/164_2016_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Heart failure with reduced ejection fraction"

1

Gulea, Claudia, Rosita Zakeri, and Jennifer K. Quint. "Prognostic differences between heart failure with preserved versus reduced ejection fraction in people with COPD." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa3500.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Clemmer, John S., W. Andrew Pruett, and Robert L. Hester. "Simulating Baroreflex Activation Therapy for the Treatment of Heart Failure with Preserved Ejection Fraction." In 2022 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2022. http://dx.doi.org/10.1115/dmd2022-1043.

Full text
Abstract:
Abstract Clinical trials demonstrate baroreflex activation therapy (BAT) reduces LV mass and blood pressure (BP) in hypertensive patients and in patients with hypertensive heart failure with preserved ejection fraction (HFpEF). It is thought that high sympathetic nerve activity (SNA) in the heart plays a role in the disease progression seen in these patients. However, the impact of BAT on hemodynamics, cardiac SNA, and disease progression during HFpEF is unknown. In the present study, we used HumMod, a large physiology model to predict the time-dependent changes of BAT during HFpEF. Our results demonstrate a progressive cardiac hypertrophy and fibrosis during HFpEF. After 6 months of BAT however, left ventricular mass was reduced (-11%), associated with decreased blood pressure, decreased cardiac SNA, and restoration of β1-adrenergic activity. Interestingly, when cardiac SNA suppression was blocked during BAT, the improvement in cardiac mass was attenuated. These simulations indicate that the suppression of cardiac SNA could be the primary determinant of the cardioprotective effects from BAT in this HF population.
APA, Harvard, Vancouver, ISO, and other styles
3

Lin, C. H., and S. M. Lin. "The Impact of Chronic Obstructive Pulmonary Disease on Patients with Heart Failure with Reduced Ejection Fraction." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hooper, Jacquelyn, Steven Shaw, Paul Callan, and Simon Williams. "150 SGLT2 inhibition in heart failure with a reduced ejection fraction: how many patients would benefit?" In British Cardiovascular Society Virtual Annual Conference, ‘Cardiology and the Environment’, 7–10 June 2021. BMJ Publishing Group Ltd and British Cardiovascular Society, 2021. http://dx.doi.org/10.1136/heartjnl-2021-bcs.147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Van, E., M. Hanewich, P. Stewart, and S. Akbarullah. "A Case of AL Amyloidosis in a Young Patient with Congestive Heart Failure with Reduced Ejection Fraction." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1729.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jargalsaikhan, N., B. Shiiter, and U. Ganbaatar. "66 Spinal anesthesia in laparoscopic cholecystectomy in a patient with congestive heart failure with reduced ejection fraction." In ESRA 2021 Virtual Congress, 8–9–10 September 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/rapm-2021-esra.66.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Anker, S., F. Zannad, J. Butler, G. Filippatos, A. Salsali, K. Kimura, J. Schnee, et al. "Design and rationale of the EMPEROR trials of, empagliflozin 10 mg once daily, in patients with chronic heart failure with reduced ejection fraction (EMPEROR-Reduced) or preserved ejection fraction (EMPEROR-Preserved)." In Diabetes Kongress 2019 – 54. Jahrestagung der DDG. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1688298.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schoebel, C., I. Fietze, and T. Penzel. "Effects of optimized heart failure medication on central sleep apnea with Cheyne-Stokes respiration pattern in chronic heart failure with reduced left-ventricular ejection fraction." In 2019 41st Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC). IEEE, 2019. http://dx.doi.org/10.1109/embc.2019.8857849.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Victor, N., G. M. Sanchez Palacios, R. Davidson, and T. Wichman. "Right Pump Impeaches the Left Pump! Chronic Thromboembolic Pulmonary Hypertension Masquerading as Left Ventricular Heart Failure with Reduced Ejection Fraction." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Curran, Fraser, Chim Lang, Colin Palmer, and Ify Mordi. "84 The prognostic significance of neutrophil to lymphocyte ratio in patients with heart failure with reduced and preserved ejection fraction." In British Cardiovascular Society Annual Conference ‘Digital Health Revolution’ 3–5 June 2019. BMJ Publishing Group Ltd and British Cardiovascular Society, 2019. http://dx.doi.org/10.1136/heartjnl-2019-bcs.82.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Heart failure with reduced ejection fraction"

1

Lian, Zheng. Efficiency and safety of catheter-based renal denervation for heart failure with reduced ejection fraction: systemic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2020. http://dx.doi.org/10.37766/inplasy2020.6.0071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Yintang, Tong Gao, Chang Meng, Siyuan Li, Lei Bi, Yu Geng, and Ping Zhang. Sodium glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0095.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dong, Zhenyu, Muyassar Yusup, Yanmei Lu, and Baopeng Tang. The effectiveness of angiotensin receptor-neprilysin inhibitor in ventricular arrhythmia in patients with Heart Failure with Reduced Ejection Fraction: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jin, Xiandu, Hao wu, Min Cui, Liping Wei, and Xin Qi. Effects of oral Omecamtiv Mecarbil in patients with heart failure and a reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0068.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zheng, Xuehui, Xiangping Ma, Yan Qi, Chang Ma, Lingxin Liu, and Peili Bu. Effects of renal denervation on cardiac structure and function in heart failure with reduced ejection fraction:a: a systematic review and meta-analysis. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Treewaree, Sukrit, Narathorn Kulthamrongsri, Weerapat Owattanapanich, and Rungroj Krittayaphong. Sodium-glucose cotransporter-2 inhibitors reduce cardiovascular outcome and improve health status in Heart failure with preserved ejection fraction: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fukuta, Hidekatsu, Hiromi Hagiwara, and Takeshi Kamiya. Sodium–glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a protocol for meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, Sisi, Jingxian Zhang, Congying Liang, Xiaochuan Li, and Xiaoping Meng. High-Intensity Interval Training for Heart failure with preserved ejection fraction: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Fukuta, Hidekatsu, Toshihiko Goto, and Takeshi Kamiya. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction: a protocol for meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2021. http://dx.doi.org/10.37766/inplasy2021.2.0025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fukuta, Hidekatsu, Hiromi Hagiwara, and Takeshi Kamiya. Effects of angiotensin-receptor neprilysin inhibitor on exercise capacity, quality of life, and cardiac function in heart failure with preserved ejection fraction: a protocol for meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2021. http://dx.doi.org/10.37766/inplasy2021.7.0076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Heart failure with reduced ejection fraction' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography